{"schema_version":"secwatch.filing_event.v1","accession":"0001082554-23-000033","form_type":"8-K","ticker":"UTHR","cik":"0001082554","company_name":"UNITED THERAPEUTICS Corp","filed_at":"2023-11-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:28.153343+00:00","generated_at":"2026-06-09T01:58:20.855138+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"United Therapeutics Q3 revenue $609.4M (+18% YoY), net income $267.6M","bullets":["Total revenues $609.4M (+18% YoY); net income $267.6M ($5.38 diluted EPS) vs $239.3M ($4.91) Q3 2022.","Tyvaso DPI sales $205.1M (+225%) drove total Tyvaso $325.8M (+26%); nebulized Tyvaso declined 38% to $120.7M.","Remodulin $131.1M (+15%), Orenitram $92.0M (+5%), Unituxin $51.3M (+11%).","R&D expense $84.7M (+28%) from TETON fibrosis studies and organ manufacturing; SG&A $127.6M (+30%).","CEO cites record quarterly revenue; pipeline data expected in 2025; management reaffirms ~$4B annual run rate."],"urls":{"canonical":"https://secwatch.observer/filing/0001082554-23-000033","json":"https://secwatch.observer/filing/0001082554-23-000033.json","markdown":"https://secwatch.observer/filing/0001082554-23-000033.md","text":"https://secwatch.observer/filing/0001082554-23-000033.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1082554/000108255423000033/0001082554-23-000033-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1082554/000108255423000033/uthr-20231101.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-09T01:58:20.855138+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"a393d45d3d4e626bfaf721a985216972160f8205","claim":"UNITED THERAPEUTICS Corp reported the quarter ended September 30, 2023 results: revenue $609.4 million, net income $267.6 million, EPS $5.38 per diluted share.","evidence_excerpt":"United Therapeutics Corporation (Nasdaq: UTHR ), a public benefit corporation, today announced its financial results for the quarter ended September 30, 2023. Total revenues in the third quarter of 2023 grew 18% year-over-year to $609.4 million, compared to $516.0 million in the third quarter of 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1082554/000108255423000033/0001082554-23-000033-index.htm","confidence":0.99,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended September 30, 2023"},{"label":"Revenue","value":"$609.4 million"},{"label":"Net income","value":"$267.6 million"},{"label":"EPS","value":"$5.38 per diluted share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}